100% Quality Guarantee
PhD-Level Technical Support
Human CD198/CCR8 Recombinant Protein (N-His)
Key Features

Human CD198/CCR8 Recombinant Protein (N-His) (GXRP01752)

SKU GXRP01752
Product Type Recombinant Protein
Species Human
Expression System E. coli
Tag N-His
€347 - €1,827

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human CD198/CCR8 Recombinant Protein (N-His)

Human CD198/CCR8 Recombinant Protein (N-His) is a recombinant protein expressed in E. coli, spanning Met1-Ile69, with an N-terminal His tag. Predicted molecular weight: 9.94 kDa. Purity: >90% as determined by SDS-PAGE. Supplied lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Applications: ELISA, immunogen, SDS-PAGE and Western blot. C-C chemokine receptor type 8 (CD198/CCR8) is a ~40 kDa protein. G protein-coupled receptor that can bind a variety of chemokines, such as CCL1, CCL8, CCL16, CCL18. For research use only.

Regulates monocyte and eosinophil chemotaxis. Undergoes internalization upon CCL18 binding, leading to induced migration and calcium flux of highly polarized Th2 cells. In microglial cells, promotes phagocytosis with CCL18 through NF-kappa-B and Src signaling pathways. Stimulation of the CCL1-CCR8 signaling axis protects the gut from acute intestinal damage.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose